0908 GMT - Novo Nordisk shares will likely remain under pressure in the near term following disappointing CagriSema weight-loss drug data, Berenberg analysts write. The company still offers superior sales growth until the end of the decade, but its CagriSema woes have brought the patent expiry of semaglutide--the main ingredient in Ozempic and Wegovy--into full focus. "Novo's obesity pipeline remains more limited than Eli Lilly's and the competitive threat of an oral GLP-1 with equivalence to Wegovy weighs heavy." The bank says consensus Wegovy expectations are too high, and notes a growing preference for Lilly's Zepbound over Novo's Wegovy. Berenberg lowers its price target to 610 Danish kroner from 725 kroner and reiterates its hold rating. Shares fall 0.9% to 524 kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
March 24, 2025 05:08 ET (09:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。